Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Contributed by: GlobeNewswire

Images

GlobeNewswire associated0

Tags

biotechnology

More Like This

GlobeNewswire associated0

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion and Exscientia Shareholders Approve the Proposed Combination

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients